Use of Baloxavir Marboxil Post-Exposure Prophylaxis to Halt an Influenza A(H3) Outbreak in a College Sports Team, November 2024.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40127195.
- Also identified by DOI 10.1093/cid/ciaf148.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Baloxavir marboxil is approved for influenza treatment and post-exposure prophylaxis (PEP). There are limited real-world examples of its use in influenza outbreaks. Here, we describe the use of baloxavir marboxil as PEP to halt an influenza outbreak among a college sports team during the 2024-2025 influenza season.
Medical subject headings
- Influenza, Human
- Post-Exposure Prophylaxis
- Antiviral Agents
- Dibenzothiepins
- Disease Outbreaks
- Morpholines
- Pyridones
- Triazines
- Thiepins